Compound News and Research

RSS

Recent data from Silence Therapeutics’ Atu111 pre-clinical study on acute lung injury

Silence Therapeutics plc, a leading RNA interference (RNAi) therapeutics company is pleased to announce that recent data in pre-clinical models demonstrated the efficacy of Atu111 in acute lung injury.

10 Sep 2012

Heptares uses StaR technology to solve structure of CRF-1 receptor

Heptares Therapeutics today announces that it has used its StaR technology to solve entirely in-house the first structure of a Family B sub-class G protein-coupled receptor (GPCR).

10 Sep 2012

Drug discovery solutions from SPT Labtech to be demonstrated at MipTech

SPT Labtech will be offering delegates at MipTec 2012 (24th-27th September, Basel, Switzerland) the opportunity to experience their innovative automated solutions for effortless drug discovery first-hand.

From SPT Labtech 7 Sep 2012

Omeros files OMS824 IND with FDA to initiate clinical trials for cognitive disorders

Omeros Corporation today announced that it has filed an Investigational New Drug Application (IND) with the U.S. Food and Drug Administration (FDA) to initiate clinical trials evaluating OMS824, the Company's lead compound from its phosphodiesterase 10 (PDE10) program for schizophrenia and other cognitive disorders.

6 Sep 2012

JQ1 compound dramatically prevents sperm production in mice

Attention men: The day may be coming soon when you can take your own birth control pill with no side effects, according to a study done by a group of scientists that includes a Texas A&M University researcher.

6 Sep 2012

Injecting capsule with heat-generating cells reduces abdominal and belly fat in mice

The injection of a tiny capsule containing heat-generating cells into the abdomens of mice led those animals to burn abdominal fat and initially lose about 20 percent of belly fat after 80 days of treatment.

6 Sep 2012

Eliminating jnk3 enzyme leads to 90% reduction in Alzheimer's plaque-forming compounds

Scientists have found that eliminating an enzyme from mice with symptoms of Alzheimer's disease leads to a 90 percent reduction in the compounds responsible for formation of the plaques linked to Alzheimer's disease.

6 Sep 2012

Prenatal exposure to piperonyl butoxide increases risk of noninfectious cough in children

Children exposed in the womb to the widely used pesticide additive piperonyl butoxide (PBO) have heightened risk of noninfectious cough at ages 5 and 6, according to researchers at the Columbia Center for Children's Environmental Health (CCCEH) at the Mailman School of Public Health and of Columbia University Medical Center.

6 Sep 2012

Scripps Florida designs new compound that shows promise against tremor ataxia syndrome

Scientists on the Florida campus of The Scripps Research Institute have designed a compound that shows promise as a potential therapy for one of the diseases closely linked to fragile X syndrome, a genetic condition that causes mental retardation, infertility, and memory impairment, and is the only known single-gene cause of autism.

6 Sep 2012

Baxter commences anti-MIF antibody Phase I trial in malignant solid tumors

Baxter International Inc. today announced that the company has begun dosing patients with malignant solid tumors in a Phase I clinical trial of a monoclonal antibody, representing the company's efforts to extend its oncology portfolio with advanced biological research and development.

From Baxter International Inc. 6 Sep 2012

UEA, IFR to study protective effects of broccoli consumption against prostate cancer

The Prostate Cancer Foundation is providing $1M of funding to the Institute of Food Research and the University of East Anglia (UEA) to study the protective effects of broccoli consumption against prostate cancer.

6 Sep 2012

CLC bio announces acquisition of Molegro

Today, CLC bio announced the acquisition of Molegro, a specialized software company focusing on molecular docking, including prediction and analysis of protein-ligand interactions, screening of compound databases for activities against a receptor, and determination of molecule similarity.

3 Sep 2012

MDA7 compound shows promise against Alzheimer's disease

A compound developed to treat neuropathic pain has shown potential as an innovative treatment for Alzheimer's disease, according to a study by researchers at Cleveland Clinic's Lerner Research Institute and Anesthesiology Institute.

3 Sep 2012

Potential new COPD drug

A study led by researchers at Boston University School of Medicine (BUSM) has shown that a compound used in some skin creams may halt the progression of emphysema and reverse some of the damage caused by the disease. When the compound Gly-His-Lys (GHK) was applied to lung cells from patients with emphysema, normal gene activity in altered cells was restored and damaged aspects of cellular function were repaired.

1 Sep 2012

GenSpera plans to initiate G-202 Phase II trial in prostate cancer

GenSpera, Inc. announced that the Medicines and Healthcare products Regulatory Agency (MHRA) of the United Kingdom (UK) has cleared for initiation a Phase II human clinical trial of its lead compound, G-202, in the treatment of prostate cancer patients who have failed prior hormonal therapy.

1 Sep 2012

VLST, Pfizer enter in-licensing agreement for anti-CD40 monoclonal antibody

VLST Corporation, a Seattle-based biotechnology company focused on the development of therapeutics for cancer and autoimmune and inflammatory disorders, today announced an in-licensing agreement with Pfizer Inc. for an anti-CD40 monoclonal antibody.

31 Aug 2012

LCZ696 could be of PARAMOUNT importance in heart failure

The first-in-class angiotensin receptor neprilysin inhibitor LCZ696 could improve treatment of heart failure, report researchers who conducted a phase II trial of the drug and found it had superior results to an alternative therapy already in use.

31 Aug 2012

Bayer submits regorafenib NDA with FDA for treatment of metastatic and/or unresectable GIST

Bayer HealthCare and Onyx Pharmaceuticals today announced that Bayer HealthCare has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the oral multi-kinase inhibitor regorafenib for the treatment of metastatic and/or unresectable gastrointestinal stromal tumors (GIST) in patients whose disease has progressed despite prior treatment.

31 Aug 2012

Janssen receives FDA Priority Review for ZYTIGA sNDA to treat mCRPC

Janssen Research & Development, LLC, announced today that the U.S. Food and Drug Administration (FDA) has granted Priority Review to the supplemental New Drug Application (sNDA) for ZYTIGA (abiraterone acetate) administered in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy.

30 Aug 2012

Genmab, Janssen partner to develop and commercialize daratumumab for multiple myeloma

Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today that it has executed a global license and development agreement with the Danish company Genmab A/S for the anti-cancer compound, daratumumab.

30 Aug 2012

Compound News and Research

Recent data from Silence Therapeutics’ Atu111 pre-clinical study on acute lung injury

Heptares uses StaR technology to solve structure of CRF-1 receptor

Drug discovery solutions from SPT Labtech to be demonstrated at MipTech

Omeros files OMS824 IND with FDA to initiate clinical trials for cognitive disorders

JQ1 compound dramatically prevents sperm production in mice

Injecting capsule with heat-generating cells reduces abdominal and belly fat in mice

Eliminating jnk3 enzyme leads to 90% reduction in Alzheimer's plaque-forming compounds

Prenatal exposure to piperonyl butoxide increases risk of noninfectious cough in children

Scripps Florida designs new compound that shows promise against tremor ataxia syndrome

Baxter commences anti-MIF antibody Phase I trial in malignant solid tumors

UEA, IFR to study protective effects of broccoli consumption against prostate cancer

CLC bio announces acquisition of Molegro

MDA7 compound shows promise against Alzheimer's disease

Potential new COPD drug

GenSpera plans to initiate G-202 Phase II trial in prostate cancer

VLST, Pfizer enter in-licensing agreement for anti-CD40 monoclonal antibody

LCZ696 could be of PARAMOUNT importance in heart failure

Bayer submits regorafenib NDA with FDA for treatment of metastatic and/or unresectable GIST

Janssen receives FDA Priority Review for ZYTIGA sNDA to treat mCRPC

Genmab, Janssen partner to develop and commercialize daratumumab for multiple myeloma

Advancing therapeutic biopolymer development eBook

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Latest News